RNA-Seq data_MM study cohort (n=73) and human myeloma cell lines

Multiple myeloma (MM) represents approximately 10 % of all hematological malignancies and patients present with a variety of clinical manifestations and diverse cytogenetic backgrounds While MM patient survival has greatly improved due to novel treatments in the last years, the disease is generally considered incurable with a median survival of approximately 6 years. Therapy resistance remains as a major obstacle, causing almost all patients to eventually relapse, underlining the persisting need to identify novel therapeutic targets and biomarkers associated with disease progression.

Type: RNASeq
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000000575	mRNA-Sequencing of 73 primary multiple myeloma (MM) samples and human MM cell lines before and after siRNA-mediated knockdown of ADAM8 (n=5 cell lines), ADAM9 (n=7 cell lines) and ADAM15 (n=5 cell lines). Paired-end sequencing was performed on a NovaSeq (Illumina). Fastq and bam files are provided for each sample.	Illumina NovaSeq 6000	107